Incyte | INCY - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agenus USD 6.21M 4.34M 2026-03
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Exelixis USD 154.56M 6.93M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 364.27M 12.54M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
MacroGenics USD 7.9M 1.81M 2026-06
Merck USD 2.86B 25M 2026-09
Moderna USD 282M 66M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Novartis USD 3.08B 58M 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09